Nucana Plc (NCNA)
NASDAQ:NCNA
Want to see NCNA full AI Analyst Report?
Top Page
Nucana
(NASDAQ:NCNA)
Select Model
Select Model
Rating:48Neutral
Price Target:
$2.00
▼(-1.48% Downside)
Action:Reiterated
Date:05/17/26
The score is held back primarily by weak financial performance (no revenue, sizable ongoing losses, and negative operating/free cash flow), with only partial support from a low-leverage balance sheet. Technicals provide a modest near-term offset as the stock is above its 20- and 50-day averages with neutral momentum, but longer-term trend remains below the 100- and 200-day averages. Valuation is also a drag because negative earnings make P/E-based support limited and no dividend yield is provided.
Positive Factors
ProTide platform and NUC-7738 clinical progress
NuCana's ProTide technology and encouraging NUC-7738 Phase 2 data create a durable competitive advantage by targeting tumor delivery and resistance mechanisms. Progress toward a potential registrational path and planned 2026 data reduce technical risk and could materially change the company's long-term commercial prospects.
Negative Factors
Pre-revenue with persistent losses
The company remains pre-revenue with sizable trailing losses and negative operating/free cash flow, meaning it must rely on external funding to sustain R&D. Persistent cash burn constrains strategic optionality and elevates execution risk if clinical timelines slip or costs rise.
Read all positive and negative factors
Positive Factors
Negative Factors
ProTide platform and NUC-7738 clinical progress
NuCana's ProTide technology and encouraging NUC-7738 Phase 2 data create a durable competitive advantage by targeting tumor delivery and resistance mechanisms. Progress toward a potential registrational path and planned 2026 data reduce technical risk and could materially change the company's long-term commercial prospects.
Read all positive factors
Nucana (NCNA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.45M
Dividend YieldN/A
Average Volume (3M)174.33K
Price to Earnings (P/E)―
Beta (1Y)1.47
Revenue GrowthN/A
EPS Growth97.61%
CountryUS
Employees20
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-7.06
Shares Outstanding4,161,971
10 Day Avg. Volume84,221
30 Day Avg. Volume174,327
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.30
Price to Sales (P/S)0.00
P/FCF Ratio-1.42
Enterprise Value/Market Cap-1.40
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit170.84
Enterprise Value/Ebitda0.52
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-8
Revenue Forecast (FY)N/A
Nucana Business Overview & Revenue Model
Company Description
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin...
How the Company Makes Money
null...
Nucana Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
64
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -69.48K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -22.65M | -20.56M | -22.48M | -31.78M | -52.15M | -41.88M |
| Net Income | -30.83M | -29.35M | -19.00M | -27.63M | -32.02M | -40.53M |
Balance Sheet | ||||||
| Total Assets | 27.55M | 40.13M | 14.77M | 27.81M | 58.25M | 77.47M |
| Cash, Cash Equivalents and Short-Term Investments | 21.53M | 32.62M | 6.75M | 17.23M | 41.91M | 60.26M |
| Total Debt | 680.03K | 909.25K | 190.00K | 396.00K | 639.00K | 371.00K |
| Total Liabilities | 5.19M | 7.41M | 8.82M | 12.92M | 19.75M | 11.93M |
| Stockholders Equity | 22.37M | 32.72M | 5.95M | 14.89M | 38.50M | 65.55M |
Cash Flow | ||||||
| Free Cash Flow | -4.24M | -6.96M | -19.41M | -26.92M | -23.68M | -24.89M |
| Operating Cash Flow | -7.24M | -6.96M | -19.12M | -26.44M | -23.16M | -23.82M |
| Investing Cash Flow | -91.34K | -188.77K | 79.00K | 2.89M | 120.00K | -3.56M |
| Financing Cash Flow | 24.48M | 24.46M | 8.18M | -53.00K | -161.00K | -98.00K |
Nucana Technical Analysis
Negative
2.03
Price Trends
1.94
Positive
2.34
Negative
3.27
Negative
Market Momentum
>-0.01
Positive
47.17
Neutral
48.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NCNA, the sentiment is Negative. The current price of 2.03 is below the 20-day moving average (MA) of 2.09, above the 50-day MA of 1.94, and below the 200-day MA of 3.27, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 47.17 is Neutral, neither overbought nor oversold. The STOCH value of 48.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NCNA.
Nucana Risk Analysis
Nucana disclosed 92 risk factors in its most recent earnings report. Nucana reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing. Q4, 2023
2.
Our internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer cybersecurity incidents, which could result in a material disruption of our product development programs, and could subject us to liability. Q4, 2023
3.
Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price. Q4, 2023
Nucana Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $6.71M | -3.36 | -60.33% | ― | 23.52% | 48.34% | |
49 Neutral | $10.47M | -0.85 | -87.05% | ― | -90.40% | 34.76% | |
48 Neutral | $8.45M | -0.25 | -253.43% | ― | ― | 97.61% | |
46 Neutral | $7.66M | -1.04 | -49.00% | ― | 11.90% | 43.46% |
* Healthcare Sector Average
NCNA
Nucana
1.98
-6.10
-75.50%
XBIO
Xenetic Biosciences
2.90
-0.17
-5.54%
IMRN
Immuron
1.00
-0.65
-39.39%
APRE
Aprea Therapeutics
0.80
-0.80
-50.00%
Nucana Corporate Events
NuCana Posts Wider Q1 2026 Loss as Cash Balance Declines
May 14, 2026
NuCana reported unaudited first-quarter 2026 results on May 14, 2026, showing a widened operating loss of £4.4 million versus £2.9 million a year earlier, driven mainly by higher research and development and administrative expenses. The ...
NuCana Sets June 8 AGM, Seeks Share Capital Restructuring and Fresh Funding Authorities
May 6, 2026
On May 6, 2026, NuCana published its 2025 UK Annual Report for the year ended December 31, 2025 and sent it, along with the notice of its 2026 annual general meeting (AGM) and proxy materials, to its ordinary shareholders. Around the same date, Ci...
NuCana Posts 2025 Results, Highlights NUC-7738 Progress and Cash Runway Into 2029
Mar 19, 2026
NuCana on March 19, 2026 reported its fourth quarter and full-year 2025 results, highlighting clinical progress with its ProTide-based oncology pipeline and a strengthened balance sheet. The company said NUC-7738 showed encouraging safety and clin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.